Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $37.32 million for the quarter.

Keros Therapeutics Stock Up 2.3 %

Shares of NASDAQ KROS opened at $10.56 on Wednesday. The firm’s 50-day moving average price is $14.66 and its two-hundred day moving average price is $41.44. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The stock has a market capitalization of $427.79 million, a P/E ratio of -2.03 and a beta of 1.39.

Analyst Ratings Changes

KROS has been the topic of a number of recent research reports. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Piper Sandler cut their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Truist Financial cut their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Finally, Scotiabank dropped their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.